Literature DB >> 6538287

Renal function and therapeutic concentrations of phenytoin.

D F Liponi, M E Winter, T N Tozer.   

Abstract

The plasma protein binding of phenytoin was studied in 40 adult patients with varying degrees of renal function impairment. The patients had stable renal function and no other condition known to alter phenytoin binding. Binding was measured by equilibrium dialysis, and the apparent affinity constant was calculated using the binding data and the measured serum albumin concentration. The apparent affinity of the drug decreased with a decrease in renal function. The decrease was most apparent in patients with creatinine clearances below 25 ml/min. The importance of altered binding on the therapeutic range is discussed, and a method of calculating equivalent therapeutic phenytoin concentrations from serum albumin and renal function is described.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538287     DOI: 10.1212/wnl.34.3.395

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Nephrology: 3. Safe drug prescribing for patients with renal insufficiency.

Authors:  Joanne Kappel; Piera Calissi
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

2.  Protein binding of phenytoin.

Authors:  E L Marble
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

3.  Hemodialysis effects on phenytoin pharmacokinetics.

Authors:  Sarah Bezzaoucha; Amine Merghoub; Caroline Lamarche; Vincent Pichette; Jean-Philippe Lafrance; Louis-Philippe Laurin; Michel Vallée; Robert Robitaille; Martine Leblanc; Robert Bell
Journal:  Eur J Clin Pharmacol       Date:  2014-01-04       Impact factor: 2.953

Review 4.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Authors:  Rob Ter Heine; Sean P Kane; Alwin D R Huitema; Matthew D Krasowski; Erik M van Maarseveen
Journal:  Br J Clin Pharmacol       Date:  2019-08-07       Impact factor: 4.335

6.  Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.

Authors:  J J Crowley; J R Koup; B J Cusack; T M Ludden; R E Vestal
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Lopinavir protein binding in HIV-1-infected pregnant women.

Authors:  F T Aweeka; A Stek; B M Best; C Hu; D Holland; A Hermes; S K Burchett; J Read; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2009-12-03       Impact factor: 3.180

Review 8.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

9.  Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.

Authors:  Stephen Weller; Julie Borland; Shuguang Chen; Mark Johnson; Paul Savina; Brian Wynne; Toshihiro Wajima; Amanda F Peppercorn; Stephen C Piscitelli
Journal:  Eur J Clin Pharmacol       Date:  2013-10-06       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.